Clinical trials: Advanced Cancer, Various, NOS
Advanced Cancer, Various, NOS
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-833923 administered alone, in combination with lenalidomide plus dexamethasone, or in combination with bortezomib in subjects with relapsed or…
- Trial name
- NCT00884546
- Testing
- BMS-833923, Lenalidomide, Dexamethasone
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer, Nerve Sheath Tumor
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody ([89Zr]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid…
- Conditions
- Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies
- Trial name
- NCT07664397
- Testing
- [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robert Flavell, MD, PhD
Advanced Cancer, Various, NOS
Existential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU)
The psychological challenges faced by patients with incurable cancer and their caregivers include an uncertain future, fear of dying and uncontrollable suffering, grief, and loneliness.
- Trial name
- NCT07312760
- Testing
- ORPHYS (ShORt-term psychodynamic psychotherapy in serious PHYSical illness), TAU (Treatment As Usual: Standard psycho-oncological care)
- Where
- 3 sites in Germany
- Volunteers
- 160 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Cancer
Multiple Ascending Dose of BMS-911543
The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to permit clinical testing at the Maximum…
- Trial name
- NCT01236352
- Testing
- BMS-911543
- Where
- 5 sites in United States, Australia
- Volunteers
- 98 people
- Sponsor
- Bristol-Myers Squibb